classic turnaround stori initi overweight price target
initi coverag share overweight rate price
target recogn name exactli synonym
strong execut given would polit character miscu part
previou manag set go forward appear quit posit us specif
compani significantli qualifi new manag team launch trifer
dialys file approv trifer iv think carv signific
posit renal space approv launch coupl exist
dialys concentr busi provid basi estim
revenu current ev
estim prove even direct correct think stock could tripl
what name readili acknowledg rockwel doesnt
exactli pristin reput creat valu sharehold opposit
fact howev think may take investor surpris new manag
team signific renal expertis charg essenti done
noth execut view trifer dialys long-last launch
real valu driver -trifer iv recent file fda ahead approv
midst think may prove one biopharma impress turnaround
trifer repres new approach renal anemia treatment iv iron esa
mainstay renal anemia manag associ document safeti
issu includ anaphylaxi cv risk iron overload trifer readili absorb
use bodi administ low dose hd treatment
repres physiolog approach hemoglobin mainten recent spherix
survey work suggest clinic profil may reson nephrologist
clear pharmaco-econom rational bundl iv iron
moreso esa repres cost center dialysi center therapi reduc
esa usag translat improv profit trifer dialys reduc use
esa though fall within bundl lessen financi benefit
provid new rule tdapa new dialysi drug approv
includ trifer iv exclud bundl reimburs asp
year creat clear financi incent center use trifer iv
risk/reward look favor ev yet one commerci product
launch on-going anoth expect start one year upon trifer iv approv
like risk/reward name think take second look
valu proposit trifer may like see would buyer level
clinic regulatori commerci risk associ pipelin product
develop therapi treatment renal diseas
revenu estim discount
assum share
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tabl content
turn-around stori weve ever seen one
new approach renal anemia treatment dialysi patient
clear pharmaco-econom rational
trifer dialys approv never launch
calcitriol first approv also never launch
old manag team new
epo iv iron domin landscap leav lot desir
esa iv iron come safeti risk
renal anemia manag evolv continu evolv respons safeti
enter trifer physiolog approach iron replac
cruise- approv overview phase trial
data two phase trial support trifer dialys approv
phase prime studi suggest esa spare benefit
data insuffici esa spare label
esa spare trial plan europ
real-world data nearer-term crucial
tdapa dialysi bundl mean trifer iv
tdapa awkward acronym deal trifer iv
wait per novemb guidanc trifer iv may actual elig tdapa
dialys huge spring board iv
get front
think iv valu driver
interest trifer iv
tdapa creat incent trifer iv use assum premium price dialys
iv iron esa treatment rate hd high much trifer
doc see need improv anemia outcom
doc top concern iv iron iron overload
coincident rmti market effort focu
attitud toward trifer move right direct
formulari access name game
doc want educ access cost-effect data
rememb dialysi use trend chang fast
ex-u strategi look eu japan partnership
model us trifer revenu approach
model ex-u royalti revenu
concentr busi big part thesi
page
driver anemia ckd
trend esrd preval case modal us
cardiovascular all-caus mortal outcom relat achiev
ferahem iv iron aranesp esa black warn
mean monthli hemoglobin level mean weekli epoetin alfa dose
distribut monthli hemoglobin level esa-tr adult hd patient
posit impact dialysi bundl payment system
evolut manag commentari tdapa trifer dialys reimburs
trifer iv bioequival pk data absolut fe absolut transferrin-bound
treatment rate anemia agent
potenti improv renal anemia outcom dialysi
nephrologist concern iv iron hd
trifer market emphas iv iron associ iron overload
trifer market emphas trifer benefit iron overload oxid stress
barrier trifer use
nephrologist advic rockwel trifer launch
esa hd share chain affili
mircera uptak freseniu dialysi center
trifer orang book-list patent expiri
sensit analysi valuat revenu
page
initi coverag overweight rate price target
compani current suffer arguabl call advers brand recognit
among investor due numer miscu previou manag set go forward
appear quit posit us specif rockwel launch trifer dialys
file approv trifer iv gain approv launch trifer
dialys contribut minim sum-of-part valuat serv
import commerci spring board trifer iv approv revenue-wis rockwel
stabl minim profit dialys busi gener revenu per
year expect trifer dialys launch year trifer iv launch potenti next
year along exist dialysi concentr busi revenu grow
current ev
estim correct think stock could doubl even tripl
readili acknowledg first thing come mind mani investor rockwel
medic histori poor manag weak corpor govern inabl
monet asset howev think may take investor surpris cours
last year new manag team well-vers renal space brought board
trifer dialys long-last launch see real valu driver
trifer iv recent file fda approv expect think may
begin stage turnaround stori
iv iron esa mainstay manag anemia caus ckd chronic
kidney diseas despit document safeti concern includ anaphylaxi cv risk iron
overload trifer repres physiolog approach hemoglobin mainten
unlik iv iron directli absorb use bodi mean
administ lower dose replenish iron lost hd session clinic data
shown reduc need esa iv iron recent spherix survey work suggest
clinic profil reson nephrologist
esa iv iron associ safeti risk ever sinc implement
dialysi bundl payment system cost center dialysi provid
incent particularli costli esa reduc use chagrin previou
manag team trifer dialys reimburs bundl new rule
tdapa new renal drug approv includ trifer iv exclud
bundl instead reimburs two year center thu incentiv
adopt trifer iv along fact exclus interest iv form
mean primari valu driver model
ev yet one commerci product launch on-going anoth expect
start one year upon trifer iv approv like risk/reward name understand
even ignor rmti tumultu histori renal space hasnt exactli vogu
investor late policymak seem recogn need incentiv innov
renal case point tdapa think take second look valu
proposit trifer may like see would buyer level approach
turn-around stori
new approach
treatment dialysi
clear
page
commercial-stag biopharmaceut compani focus therapi
treatment patient end-stag renal diseas esrd chronic kidney diseas ckd
lead asset trifer iron mainten therapi deliv bioavail iron directli bone
marrow repres physiolog approach iron replac hemodialysi
current standard care high dose iv iron also reduc esa use trifer dialys fda
approv current launch small- medium-s dialysi organ
iv formul fda review potenti launch larg dialysi
organ compani strategi bring therapeut market unit
state util partner develop commerci therapeut intern
market also establish manufactur supplier leader deliv
hemodialysi concentrates/dialys dialysi provid distributor
page
productcatalystanticip timingtrifer dialysatecomm commerci launch trifer dialys us sdo/mdo ongoingdisclos real-world data esa spare benefit trifer dialys pjc pilot program trifer iv may begin trifer iv approv pjc ivpotenti fda approv trifer iv us commerci launch trifer complet on-going pk trial need china approv follow regulatori canada regulatori file estim peak market opportun eu japan partnership estim eu peak revenu japan ex-uspotenti china apporv trifer dialys trigger mileston payment partner wanbang compani estim peak market oppi phase trial requir ema includ esa-spar primari endpoint pend eu partnership readout phase trial requir ema includ esa-spar primari eu file may also file esa spare data fda add ipex-u expiri formul patent trifer iv expiri formul patent trifer iv trifer dialys
approv
never launch
approv
also never
old manag
team
think stretch say rockwel suffer advers brand recognit among
investor stem prior manag team fail strategi monet asset
includ trifer dialys prior team ultim oust new team
includ stuart paul angu smith fortun start right ship said
dont want dwell fail strategi prior manag think import
discuss certain aspect contextu current strategi walk
histori see case studi consequ lax corpor
strategi focus develop bring market proprietari renal
therapi leverag compani expertis renal space dialysi
concentr busi accordingli compani in-licens right sfp solubl ferric
pyrophosph brought drug clinic develop includ
odac panel januari approv trifer dialys though compani
request esa-spar label claim rebuf fda want suffici clinic data
howev leadership former board chair ceo rob chioini cfo
thoma klema trifer never launch compani instead pursu strategi gain
reimburs outsid dialysi bundl ultim unsuccess
compani calcitriol experi similar compani acquir anda
gener vitamin analogu treatment shpt secondari hyperparathyroid patient
esrd though approv august manufactur issu delay launch
indefinit new manag team announc march strateg
review profit commerci us isnt viabl vitamin product price
lower cost produc calcitriol
prior manag team failur execut commerci launch coupl poor
investor commun stock under-perform came head activist
investor richmond brother disclos ownership compani eventu led
fire ceo chioini cfo klema may turn messi separ
fire execut file whistleblow suit later settl around
time auditor plant moran resign concern crucial updat
trifer dialys reimburs statu disclos either withheld
audit process rmti financi report defici
saga investor somewhat wari compani
said think appoint stuart paul announc august bring
extens renal experi along full slate capabl biopharma oper creat
quintessenti turnaround setup trifer detail herein
page
herein give quick refresh caus anemia dialysi patient better understand
trifer benefit standard-of-car iv iron esa anemia condit mark
insuffici red blood cell low hemoglobin hb level frequent seen patient
ckd md inflammatori diseas cancer condit chronic kidney diseas aris
kidney becom damag long period time gradual lose function often
lead kidney failur esrd diabet high blood pressur heart diseas often play
lead role develop progress ckd patient progress esrd
requir form renal replac therapi includ kidney transplant dialysi
patient gener develop anemia two primari reason iron defici low level
erythropoietin epo healthi kidney cell call peritubular fibroblast sens level
oxygen blood secret epo stimul red blood cell product
erythropoiesi bone marrow maintain blood oxygen level optim level howev
ckd progress number peritubular fibroblast reduc epo secret
decreas lessen product build block hemoglobin need
product ckd patient often iron defici impair dietari iron
absorpt iron sequestr impair iron avail due inflamm elev
hepcidin combin factor lead anemia tend becom sever
patient ckd worsen patient advanc dialysi condit exacerb
hemodialysi treatment lab test result small amount blood loss anemia
lead fatigu decreas qualiti life addit increas risk cardiovascular
complic hospit exacerb condit
driver anemia ckd
page
incid preval ckd frequent caus diabet hypertens
increas segment us popul patient undergo
hemodialysi given year almost hemoglobin
trend esrd preval case modal us
unit state renal data system usrd annual data report epidemiolog kidney diseas unit state nation
institut nation institut diabet digest kidney diseas bethesda md
page
epo iv iron domin landscap leav
lot desir
prior launch esa renal anemia treatment gener limit red blood cell
infus estim seen use dialysi patient howev
transfus came multipl health risk includ transmiss blood born ill allo-
sensit foreign antigen could delay prevent kidney transplant esa first
came scene approv amgn epogen allow
reduct transfus patient treat mean hemoglobin g/dl essenti esa
recombin human erythropoietin use concomitantli iv iron design
stimul product rais hemoglobin level estim dialysi
patient treat esa along iv iron becam standard care renal anemia
howev seriou safeti risk associ treatment paradigm becam
evid larg trial demonstr treat higher hb level g/dl use higher
dose esa associ increas risk advers event particularli cv event
stroke see exhibit safeti issu fda issu black box warn
see exhibit esa warn elev cv event risk fda also reduc
target hb g/dl esa label recommend initi esa treatment hb
call esa dose reduct hb level approach dialysi
patient note also esa carri black box label relat cancer progress
found use esa rais hb level g/dl stimul progress cancer
cardiovascular all-caus mortal outcom relat achiev
safeti risk
page
normal hematocrit studi nh period patient dialysi hemoglobinckd patient dialysi type ii diabet hemoglobin g/dl previous administ epoetin alfa g/dlhemoglobin higher vs lower vs vs vs achiev hemoglobin level vs vs endpointall-caus mortal non-fat miall-caus mortal mi hospit chf strokeall-caus mortal mi myocardi ischemia heart failur strokehazard ratio rel risk outcom higher groupall-caus mortalityall-caus mortalitystrokehazard ratio rel risk patient hemodialysi coexist chf cad hematocrit epoetin alfa exhibit
ferahem iv iron aranesp esa black warn
describ patient treat esa gener receiv iv iron supplement
patient need iron replet esa treatment effect often
shortag avail iron addit safeti concern esa manifest sinc
dialysi move bundl payment system patient receiv iv iron
howev iv iron carri safeti risk
show tabl exhibit approv iv iron iron-carbohydr complex
administ rel high dose taken macrophag iron store
macromolecular complex metabol releas bind transferrin
carri bone marrow product carbohydr moieti thought
contribut anaphylaxi risk fact ferahem carri black box warn anaphylaxi
risk due inflamm present hd patient elev hepcidin hormon regul iron
metabol reduc effici iron deliveri bone marrow may contribut
function iron defici despit high dose high iron store trial point
increas iv iron use associ higher risk hospit death particularli
patient iron overload though isnt clear-cut consensu serum ferritin level
constitut overload
still debat optim use iv iron manag anemia hd patient spherix
survey feedback discuss herein indic doc divid whether dialysi
commun overal overus iv iron hd patient note vifor recent carri larg
trial examin effect two iv iron dose strategi hd low-dos
reactiv regimen intend maintain patient near lowest accept iron limit high-
dose proactiv regimen allow higher iron dose ferritin/tsat level pivot
trial show non-inferior high-dos group low-dos group safeti high dose
arm actual numer lower rate safeti event low dose arm lower esa
use blood transfus high dose arm without elev risk infect trial
shown high dose iv iron regimen associ detriment effect mace
infect think would strengthen case trifer consist kol
feedback weve gotten subject howev judg mani letter editor recent
publish nejm find trial along spherix survey work sens
mani nephrologist still harbor concern iv iron safeti
page
thu esa carri safeti risk use combin iv iron may carri
risk think there ampl room altern safer treatment see use
address renal anemia describ
manag
evolv
continu evolv
respons
describ herein dialysi bundl payment system implement
came larg respons sever issu regard esa drive factor escal
medicar esa expenditur near high proport dialysi patient hb
level greater g/dl roughli half clinic trial fail show improv
outcom esa dose higher hb level desir creat financi incent
constrain esa use effect bundl packag servic provid dialysi patient
direct medicar administr establish fix compens amount dialysi
facil result bundl went effect esrd-rel drug includ esa
longer separ billabl chang esa profit center cost center dialysi
provid thu encourag facil decreas use
bundl along esa safeti concern reduc hb target caus fairli drastic
reduct esa use reduct hb level dialysi patient sever chart
illustr trend see exhibit essenti take away trend
current renal anemia standard care esa iv iron around entrench
year doesnt mean market unchang face econom incent
chang prescrib trend accompani safeti concern esa use cut basic half
rel short period suggest us rockwel success make case
dialysi provid trifer fact provid clinic benefit cost save drive
uptak sdo/mdo
page
productinf dexferrumferrlecitvenoferferahemeinjectafertrifericyesyesyesyesyesnocomplexfirst us pediatricsadult pediatricsadult pediatricsadult adult adult molecular weight iron per hdhdd-ckd rate per mg/hrinfus durat per dose-ov hrover least minov least minov least hour durat hd salt iron complex pyrophosph citratenonstoichiometr magnetit coat polyglucos sorbitol carboxymethyleth carboxymethyl dextran complex polynuclear iron -hydroxid sucros -hydroxid carbohydr complexcomplex sodium ferric glucon sucroseliquid complex ferric oxyhydroxid dextran polyglucoseferr pyrophosph citratebox warn anaphylactic-typ reactionswarn hypersensit reactionswarn hypersensit reactionsbox warn anaphylactic-typ reactionswarn hypersensit reactionsida patient hdd-ckdbroad idaida patient ckdbroad idabroad ida dextransodium ferric glucon complex sucroseferumoxytolferr carboxymaltoseida patient hdd-ckdwarn hypersensit reactionstot iron dose per treatment coursecalcul use desir least annuallycomplex carbohydr backbon exhibit
mean monthli hemoglobin level mean weekli epoetin alfa dose
unit state renal data system usrd annual data report epidemiolog kidney diseas unit state nation
institut nation institut diabet digest kidney diseas bethesda md
distribut monthli hemoglobin level esa-tr adult hd patient
unit state renal data system usrd annual data report epidemiolog kidney diseas unit state nation
institut nation institut diabet digest kidney diseas bethesda md
page
enter trifer physiolog approach
trifer ferric pyrophosph citrat offer altern iron replac option current iv iron
therapi first approv januari replac iron maintain
hemoglobin adult patient hd-depend ckd hdd-ckd
trifer structur function distinct iv iron refer exhibit exhibit bind
immedi transferrin carri iron bodi soon enter blood
travel bone marrow product occur recal iv iron product
absorb physiolog manner trifer iv iron dose instead bind
immedi transferrin trap store tissu liver
associ iron overload inde major us dialysi patient ferritin level
industri guidelin
page
currently-approv formul administ via dialys liquid use filter blood
hd see exhibit hemodialysi treatment note dialys trifer avail
liquid single-pati dose form approv powder packet multiple-us
formul approv premis iron mainten therapi replac
iron lost hd session small amount blood trap dialysi
equip lost vascular access blood draw etc compani estim hd-
relat gi iron loss averag iron per year match amount
iron replac trifer treatment
approach replac amount iron lost treatment without increas iron store
also translat uniqu label trifer versu approv iv iron trifer
product indic hemoglobin mainten show trifer label side side
venof label illustr distinct trifer indic replac iron
maintain hb adult hd patient venof indic say treatment iron
defici anemia say noth mainten addit trifer carri
contraind fewer warn precaut note venof requir observ
hypersensit least minut post-administr also carri warn iron
page
rockwel trifer market materi effect commun advantag trifer offer
macromolar iv iron summar trifer donat iron directli avoid iron
sequestr encount iv iron mean iron immedi deliv bone marrow
hb format restor approxim amount iron lost hd treatment mean
patient iron balanc proactiv maintain prevent develop iron defici
state without iron overload avoid function iron defici exacerb
page
data two phase
approv
cruise- approv overview phase trial
approv trifer support two phase studi refer cruis studi
continu replac use iron solubl equival provid detail
two random control clinic trial ident design refer
fishban et al investig test hypothesi trifer dialys could
sustain iron deliveri erythropoiesi effect placebo maintain
hemoglobin concentr hemodialysi hd patient total patient includ
studi trial design three
run-in period week patient receiv studi drug
random treatment period single-blind treatment week
open-label treatment period determin long-term safeti
primari endpoint studi chang hemoglobin baselin end
treatment stage secondari endpoint includ chang reticulocyt hemoglobin
content chr chang serum ferritin level oral iv iron supplement prohibit
dose erythropoiesis-stimul agent esa held constant
patient meet criteria entri stage studi random receiv
triferic-tr placebo dialys note patient stage random treatment
period roll stage open-label treatment follow event
ferritin ug/l
hb becam g/dl g/dl
hb g/dl associ hb increas g/dl week
week treatment elaps
report studi patient receiv trifer met primari efficaci endpoint
treatment differ g/dl favor trifer mean chang hb baselin end
treatment combin result specif trial shown exhibit
patient receiv trifer g/dl g/dl decreas hb vs g/dl
g/dl decreas placebo respect posit benefit also
observ ferritin level reticulocyt hb content transferrin satur tsat overal
result indic better mainten hb level patient treat trifer
page
assess endpoint chang baselin end treatment hemoglobin
ferritin reticulocyt hemoglobin transferrin satur
trifer approv base data concern rais adcom review
true mean studi outcom mention patient stage trial
roll stage one four event occur includ specif chang hb
ferritin level reach pre-defin week treatment endpoint treatment
plan one year minor patient complet full week due protocol-
mandat chang anemia manag chang esa and/or iron dose due
chang hb ferritin level thu hb chang baselin end-of-treat period
includ hb level patient chang esa dose prior week period well
made end period complic interpret result
break data triferic-tr patient placebo
patient complet stage reach week random treatment
proport patient requir protocol-mand chang esa dose similar
trifer patient placebo patient patient reason
differ treatment group patient alloc receiv trifer
decreas esa dose due hb g/dl vs placebo patient
page
hg mean sd baselin eot mean sd ferritin mean sd baselin eot mean sd reticulocyt hb chr mean sd baselin eot mean sd tsat mean sd baselin eot mean sd
patient low hb hb g/dl placebo patient increas esa dose
vs trifer patient gener data indic improv deliveri iron
trifer rel placebo though note difficult draw infer entir
review patient protocol-mand chang anemia manag
protocol-mand chang anemia manag
patient hb g/dl associ hb increas g/dl week
modifi fda adcom publish result
overal triferic-tr patient placebo patient
complet random treatment period stage patient discontinu due non-
protocol-mand chang anemia manag trifer pbo
treatment-emerg advers event teae report similar rate group
trifer placebo patient receiv trifer least one teae
led treatment discontinu vs placebo group total
page
 stage criteria iron dose increas decreas drug suspend consecut phase prime
studi suggest
death studi none consid relat studi treatment attribut
importantli instanc anaphylaxi report trial inde none
report administr trifer administ even patient histori
allerg reaction iv iron
prime physiolog replenish iron mainten equival studi phase
trial determin abil trifer dialys reduc prescrib esa use maintain hb
level recommend rang hemodialysi hd patient potenti support
addit esa spare trifer label double-blind placebo-control studi enrol
hd-ckd patient random receiv triferic-tr placebo dialys
primari efficaci endpoint percent chang baselin esa dose end
treatment secondari endpoint includ iv iron use safeti studi treatment last
week iv iron usag allow esa dose could adjust first week
report result demonstr reduct prescrib esa dose triferic-tr
patient vs placebo end treatment trifer pbo analysi
supplement trifer group requir less iv iron overal though patient
requir supplement iv iron receiv dose compar placebo patient trifer
wk pbo wk overal trifer gener well toler similar
trifer placebo sae trifer placebo report group
result promis result support addit esa-spar label
trifer discuss think real-world data go import
establish valu trifer iv
two exhibit highlight safeti efficaci comp iv iron trifer
howev warn realli appropri make direct comparison two
trifer evalu mainten therapi intend use iron replet patient
idea decreas need iv iron esa therapi make comparison
apples-to-orang exercis howev safeti front would highlight lack
anaphylaxi risk trifer said iv iron
page
page
indic iron defici anemia iron defici anemia iron defici anemia companyrockwel medic american regent privat drugtrifericvenof iron sucros ferahem ferumoxytol studyphasetri design patientsprimari endpointlength trial trifer placebo trifer placebo trifer placebo trifer placebo venof epo fix epo fix ferumoxytolplaceboferumoxytol iron sucroseferumoxytol oral ironevalu patient hgb mean sd patient w/ hb inc hb eot mean sd g/dl differ g/dl se p-valu ferritin eot mean sd chr eot mean sd tsat eot mean sd u/wk u/wk mean chang mean mean differ mean confid interv -- -- -- -- -- -- -- -- -- -- -- -- p-valu -- -- -- -- -- -- -- -- -- -- -- -- baselin characteristicstrifericplacebotrifericplacebovenof epo fix epo fix ferumoxytol placeboferumoxytol iron sucroseferumoxytol oral hemodialysi iv iron exposur blood hemoglobin fda label per publish result includ data cruis hb g/dl ferritin ng/mll venof vs histor controlsam cruis limit esa u/wksam cruis limitedto esa hb eot day day day week day chang hemoglobin tp baselin tp week follow first cours esa dose trifer vs placeboesa chang weeksrandom trifer vs placebohdd-ckd mean hb g/dl tsat mean serum ferritin ug/l hb end treatment end stage week week run-in week treatment vs placebo ferahem vs iron sucros adult particip hb g/dl tsat histori oral iron therapi oral iron could use week week broken dialysi trial vs oral week baselin hb g/dl hb baselin trial trial phase exhibit
page
indic ckd ckd ckdcompanyrockwel medic american regent privat drugtrifericvenof iron sucros ferahemestudymix studiesphasemultipletri design mixedpatientshdd-ckdlength trial mixedtrifer placebovenoferferahemeor ironevalu patient event fistula site respiratori tract tract post-market safeti includ non-dialysi dialysisstudi hdd-ckd patientspt anaphylactic-typ reaction reportedhdd-ckd mean hb g/dl tsat mean serum ferritin ug/l mixedprim cruis phase trial patient stage daysphas ckd patient seriou hypersensit reaction report pt first five year launch faer databas list anaphylact reaction fatal part led black box warn anaphylaxi data insuffici
esa spare
trial plan
real-world data
nearer-term
rockwel initi sought trifer label statement esa reduct adult hd patient
basi phase data describ previous howev fda fairli blunt see medic review
dismiss possibl base data point studi protocol
state exploratori trial whose statist consid descript rather
exclus fda went clarifi larg phase trial need conduct evalu
efficaci trifer indic
front reach agreement ema develop path trifer iv
eu addit exist bodi data singl phase trial requir support
registr primari endpoint prescrib dose esa trifer arm compar
standard anemia manag control arm week actual time trial
eu file depend outcom discuss potenti eu partner look
think like scenario initi data data may also
serv basi gain esa spare label statement us
ideal circumst perhap differ manag team direct trifer
clinic develop possibl drug could launch esa spare label
point entir necessari given trifer dialys label fact trifer
iv refer trifer dialys clinic data given eu esa-spar studi
hasnt even start like wont complet view import
dialysi provid real-world data demonstr trifer pharmaco-
econom benefit term esa spare trifer label includ esa spare
claim inde similar recent feedback manag indic tiw
label hif vadadustat isnt necessarili critic use dialysi set
evalu tiw protocol pilot program long tiw data
work manag realiz import gener make avail real-
world data trifer order better elucid drug pharmaco-econom valu dialysi
recent sign agreement mid-tier dialysi clinic provid collect provid
real-world trifer data importantli may includ data point addit esa
reduct includ reduct hospit rate trifer initi approv
commerci launch last month activ sampl program
encompass clinic total still program manag
indic experi signific stockpil real-world data esa
spare hospit reduct etc alreadi site would expect see
data later year think inform trifer iv price kind real-
world benefit mdo see drug pilot center
govern trifer adopt protocol also think possibl
pilot trifer iv clinic trial approv hand could mean quicker uptak
page
tdapa dialysi bundl mean trifer iv
current bundl payment system formal known esrd prospect payment
went effect pay dialysi provid fix amount adjust per
person per treatment dialysi epo iv iron vitamin lab test oral medic
iv equival includ oral iron vitamin prior paid esrd provid
dialysi treatment two part composit rate separ reimburs drug servic
one immedi impact implement dialysi bundl dialysi drug
chang profit-cent provid cost-cent describ
interestingli prior manag team initi posit trifer ideal suit
bundl reimburs system see exhibit corpor deck
decreas need esa iv iron would creat financi incent dialysi
provid util trifer dialys
posit impact dialysi bundl payment system
promot innov bundl payment system
howev implement esrd pp rais signific polici question potenti
financi incent conflict good medic practic stifl innov renal
space given concern chang made plan sinc
implement esrd pp exampl discuss launch
note initi plan includ oral drug manag bone miner
disord within bundl defer inclus push back
defer
page
deal trifer iv
import trifer iv provis known tdapa transit drug add-on
price adjust provis new dialysi therapi exclud bundl
believ creat econom incent util trifer iv
tdapa origin incarn meant trifer dialys includ bundl
initi guidanc tdapa mechan aros late need clarifi
dialysi product would incorpor bundl origin propos new
inject iv product approv indic esrd pp
function categori new product would reimburs use transit drug add-on price
adjust minimum two year time util data would
gather time drug would includ within new function categori
bundl base rate could modifi account new drug
guid new inject iv dialysi product indic condit fit within
esrd function categori anemia manag would consid reflect esrd
pp bundl separ payment follow includ trifer dialys within
dialysi bundl
prior manag thought trifer dialys exempt tdapa
never actual launch drug
howev clarifi calcimimet fell esrd function categori bone
miner metabol money initi includ dialysi base rate categori
mean tdapa adjust would use reimburs iv/inject calcimimet
amgn parsabiv approv see exhibit previou manag team
look exampl parsabiv reimburs outsid bundl tdapa
mechan felt trifer met criteria grant transit add-on payment
given belief instead launch trifer within bundl prior team pursu
add-on reimburs interact legisl other provid
extrem littl visibl process time decis see progress prior
manag team commentari issu exhibit
final june rmti board determin base feedback cmss innov
center dialys trifer wasnt like obtain add-on reimburs near-term
chang commerci strategi plan dialys trifer launch within bundl
howev subsequ chang tdapa guidanc mean trifer iv elig add-on
reimburs discuss
page
evolut manag commentari tdapa trifer dialys reimburs
note quotat prior novemb come rmti prior manag team pjc-ad emphas color red use reflect instanc prior manag team
disagre trifer dialys reimburs green reflect agreement accept trifer dialys reimburs decis
page
datemanag commentari establishedapathwaythatwouldallowdrugsliketriferictobereimbursedthroughthetransitionaladd-on mechan believ trifer fall squar within pathway base inform publish late fact recent grant tradit add-on payment anoth drug renal space clear preced roadmap establish discuss work process obtain form reimburs trifer process fluid formal structur sequenc event top prioriti work great sens urgenc paul met seek add-on reimburs dialysi dialys trifer gain clariti around expect reimburs level meet took place first week ceo although tell product meet last week final rule mean rockwel medic dialys formul trifer definit price insid bundl word current version trifer separ paid therapi esrd set given price reimburs expert help us map potenti outcom prepar possibl care analyz novemb rule assist outsid expert determin move ahead commerci launch insid bundl dialys trifer work final commerci manufactur scale-up implement plan target launch first half soon practic stuart paul appoint ceo effect septemb addit trifer meet guidelin new innov therapi receiv add-on reimburs also saw amgen new bone miner drug secur add-on reimburs back congression support initi told would bundl month initi want reiter expect success gain add-on reimburs trifer felt import provid background clariti one last step add-on reimburs feel confid complet believ cusp gain reimburs book trifer sale govern bundl reimburs payment incentiv dialysi provid use product deliv qualiti patient outcom reduc cost per treatment exactli trifer demonstr trifer deliv iron bone marrow maintain hemoglobin without increas iron store trifer significantli reduc expens esa use along substanti reduct nurs hour trifer ideal suit succeed bundl reimburs system success oper busi strong relationship highli concentr custom familiar rockwel trifer coupl ideal bundl reimburs system put us great posit captur dialysi market quickli upon commerci launch trifer announc previous grant uniqu product reimburs code last week came final rule detail agenc pay servic provid medicar beneficiari expect trifer bundl reimburs therefor alreadi account bundl payment made healthcar provid custom convert trifer paid trifer portion payment origin alloc iv iron easi shortsight thing would book sale bundl could report sale may made investor feel good moment mayb would result short-term pop share price would wrong decis tri convinc us otherwis sharehold best interest heart done everyth right regard posit trifer success last leg race expect cross finish line soon grant uniqu product reimburs j-code trifer becam effect januari year novemb inform us trifer go part esrd reimburs payment bundl payment felt howev trifer met criteria grant transit add-on payment would place trifer reimburs outsid bundl period time began discuss discuss medicar policymak on-going bundleforreimburs thiswasth initialresponsewehad expect plan go congress begin work support add-on reimburs trifer made first trip meet member conbress late februari last year sinc time made mani trip sever product meet wait per
may actual
elig tdapa
respons stakehold concern polici discourag develop therapi
fit exist function categori last novemb updat tdapa polici
indic new dialysi drug biolog approv januari
regardless function categori elig tdapa elig reimburs
two year
believ trifer iv consid qualifi new drug separ j-
code reimburs outsid bundl add-on payment two year
iv trifer approv given go-ahead reimburs tdapa
mechan go risk trifer iv wont consid new drug light
prior trifer dialys approv reimburs insid bundl instead howev
recent issu preliminari recommend establish separ j-code
dialys trifer powder packet distinct j-code ampul think serv
nice preced consid trifer iv distinct new drug also support
drug new drug approv pathway
may make tdapa chang like odd benefit
encourag current form tdapa provid incent adopt
innov renal therapi perfect instanc stakehold take issu new
therapi reimburs argu asp definit reflect averag sale
price purchas includ larg purchas group mani dialysi
facil may abl purchas asp result reimburs
doesnt cover cost new drug provid
addit remain open debat whether two year exclus bundl
suffici drive signific adopt new renal therapi physician provid
deter util new therapi know within two year fold
bundl howev consid recent direct move tdapa focu
hh initi like kidneyx commentari hh secretari highlight need
renal innov believ addit chang made tdapa
benefit longer time period exclus bundl may see addit
clariti releas esrd payment rule
page
get front
dialys huge spring board iv
rockwel plan market trifer dialys mdo/sdo independ dialysi clinic
treat us hd popul discuss later think
product fraction size trifer iv said think dialys launch year
import come trifer iv launch lay groundwork term build
physician awar educ engag kol creat real-world evid given
drug histori think benefici new team time hone messag
trifer posit renal anemia manag paradigm iv formul
describ previous trifer compet standard care iv iron esa think
confer tangibl clinic econom benefit agent hif hypoxia-induc factor
compound meant provid altern esa also launch around time
led fgen roxa next year also reimburs tdapa mechan
remain seen hif launch affect trifer launch inde shift esa
could mitig trifer cost-sav advantag dont see direct
competitor trifer said one reason proceed trifer dialys launch
year build awar get ahead hif launch gain share-of-voic
renal space may prove wise renal anemia space heat
uptak trifer dialys like take time first order busi educ
physician trifer get trifer ad formulari chang anemia
manag protocol includ trifer manag indic gener take
month time make first call trifer formulari protocol
even major activ sampl site expect transit pay
drug certain step must taken first irb review arent necessarili look
trifer dialys put big revenu number anytim soon
page
think iv valu driver
also develop iv formul trifer describ herein expect
main valu driver product stock
spa special protocol assess fda agre file iv formul
base equival approach trifer dialys without addit large-scal
safeti efficaci trial equival trial complet iv formul met
bioequival criteria pk paramet total iron transferrin-bound iron see exhibit
pre-nda meet june fda indic equival studi would
suffic nda submiss trifer iv pathway new drug ensur
regulatori januari nda submit fda may
approv decis expect launch
trifer iv bioequival pk data absolut fe absolut transferrin-bound
manag indic exhibit strong prefer trifer iv
wait iv approv launch segment iv prefer less
disrupt clinic workflow anemia protocol unlik dialys iv form allow
individu patient dose addit econom incent use trifer iv reimburs
outsid bundl two year realiz cost save reduc esa/iv iron use go
import factor ldo adopt
exist relationship baxter dialysi concentr
busi manag prior experi renal space manag
character commit partner rockwel sens ldo
like adopt trifer iv soon approv exist
relationship also freseniu financi stake renal product like venof
compet trifer dont model robust rapid trifer iv adopt
freseniu
remain seen sdo/mdo respond trifer iv financi incent creat
tdapa model modest use iv segment assum clinic adopt trifer
dialys gener stick protocol updat
note outsid us dialysi clinic primarili use dri bicarbon cartridg
compat trifer iv assum primari driver ex-u sale well
interest
trifer iv
page
incent trifer
iv use assum
premium price
almost goe without say approv reimburs outsid bundl
year tdapa dialysi clinic clear econom incent use iv trifer
two year dialysi clinic benefit cost save due reduc use esa iv iron
reimburs trifer essenti cost better especi may negoti
price lower asp
trifer dialys wac per treatment powder packet assum
domin volum assum translat net revenu
rang model initi reimburs
could conceiv price iv form signific premium constraint
price equat trifer iv initi outsid bundl co-pay consider
take account dialysi organ negoti price asp higher price
think price decis ultim driven real-world find term save
trifer iv provid esa reduct fewer hospit etc look data
prime trial show trifer associ reduct esa use
assum dialysi center current spend per dialysi treatment
per patient annual esa esa reduct would translat save per
patient per year base math model trifer iv net revenu annual
model base-cas assumpt trifer iv fold bundl
two year point net price contract see exhibit
page
better understand current renal anemia trend environ trifer launch
highlight herein physician feedback partner spherix global insight
conduct quarterli survey nephrologist focus treatment trend space particularli
renal anemia set feedback come survey field march
includ feedback nephrologist manag averag in-cent hd patient
survey field decemb includ feedback nephrologist
averag in-cent hd patient manag believ nephrologist feedback
import monitor trifer dialys progress trifer iv launch
nephrologist report fulli two-third hd patient manag treat
iv iron see exhibit venof clearli domin player captur iv
iron use physician primarili associ freseniu financi stake venof
report highest hd share venof davita-associ physician report
venof share mdo/sdo hospit report rel ferrlecit use
doc report esa use almost hd patient see exhibit expect
associ doc report epogen captur esa share convers fresenius-
associ doc indic mircera captur esa use mdo/sdo also report
mircera use hospit report epogen make esa use
surprisingli given trifer rather beleagu histori survey doc report
use trifer gener rmti sampl demonstr program select clinic
treatment rate
hd high
much trifer
treatment rate anemia agent
page
doc see
need improv
nephrologist rank potenti improv renal anemia outcom
dialysi set high high rank low think
bode well recept trifer dialys trifer iv
potenti improv renal anemia outcom dialysi
question degre think renal anemia outcom improv dialysi set need improv
patient well-manag opportun improv outcom patient benefit
page
iv iron iron
term safeti iv iron major nephrologist report high level concern
iron overload doubl percentag doc report high level
concern safeti issu anaphylaxi increas infect risk
inflamm oxid stress interestingli highest share doc report low
concern anaphylaxi suggest though seriou iron overload
doc rel consist sinc earli indic serum ferritin level
mid- high- get concern safeti estim cours year
one-quart iv iron-tr hd patient mainten dose put
hold due elev tsat ferritin
overal nephrologist appear somewhat divid question iv iron overus
respond agre dialysi commun overus iv iron hd patient
compar respond disagre statement interestingli respons
chang survey lower percentag disagre iv iron overus
nephrologist concern iv iron hd
question serum ferritin level get concern safeti relat iv iron administr degre concern administr iv iron
dialysi patient concern extrem concern cours year percent hd patient treat iv iron mainten dose place
hold due elev ferritin tsat level
question pleas rate level agreement follow statement scale strongli disagre strongli agre
page
coincident
rmti
inde sinc launch trifer begin may rockwel place particular
emphasi iv iron associ iron overload see trifer market materi exhibit
align well physician iv iron concern
trifer market emphas iv iron associ iron overload
trifer market emphas trifer benefit iron overload oxid stress
page
trifer move
right direct
nephrologist respons favor certain aspect trifer
suggest rockwel initi physician educ effort effect though
acknowledg earli draw huge conclus physician attitud toward trfieric
notabl doc survey march year agre trifer physiolog way
treat iron defici hd patient survey similarli doc
survey agre trifer safer tradit iv iron formul
rockwel messag continu reson doc certain aspect
strategi like kol engag start take shape inde drug launch last
month think reflect futur survey feedback watch trend
question pleas rate agreement follow statement disagre agre
page
formulari access
name
lead barrier trifer use lack formulari access design doc
barrier use primari barrier use lack familiar trifer also
frequent cite barrier doc select primari barrier doc
next-most cite barrier use belief offer benefit iv iron nobodi
talk see exhibit
sens fact doc chose trifer lack formulari access lack
familiarity/knowledg benefit iv iron lack promot top barrier use
actual bode pretti well launch view barrier emin fixabl
activ launch drug barrier lower physician list qualiti
clinic data deliveri central loop use solid bicarbon system
trifer dialys incompat see less like sway rmti launch
barrier trifer use
question describ use trifer center checck appli indic primari
page
cost-
dont see feedback anticip trifer particularli help inform
time survey field trifer hadnt launch said
show exhibit physician gener call rockwel provid educ
drug efficaci safeti profil particularli relat establish iv iron product access
dialysi provid cost-effect data includ real-world
nephrologist advic rockwel trifer launch
page
rememb
chang fast
recal launch trifer dialys year non-ldo sdo/mdo
independ provid refer includ feedback survey
show segment mircera hd share jump
aranesp share plung time period see
exhibit fact trend continu mircera sdo/mdo/independ share climb
aranesp share fell epogen fell think mircera strike
share gain segment tune six month bode well adopt
trifer dialys assum success secur inclus treatment protocol
matter would argu rapid adopt mircera freseniu clinic see exhibit
portend well trifer iv uptak assum comfort
clinic econom profil
esa hd share chain affili
question percent hd patient treat esa follow brand cross tabul primari chain affili subgroup
caution small hospit
mircera uptak freseniu dialysi center
page
ex-u strategi look eu japan partnership
rockwel secur collabor agreement china partner wanbang
trifer dialys like trifer iv well wanbang fund two
on-going pk trial need cfda approv potenti china file later year
approv term agreement elig royalti net sale
low- rang receiv mileston upon approv model
amort time
ema guidanc clinic program need eu approv hand
process identifi partner europ assum fund partli fund esa-
spare trial believ disclosur partner europ and/or japan potenti later year
could nice catalyst rockwel could bring non-dilut financ form up-front
payment model royalti geographi well latam
conservat model cash inflow relat up-front payment
page
think trifer dialys conserv repres opportun assum
market share sdo/mdo patient annual net price per
patient base esa spare potenti initi exclus bundl describ
previous think iv iron could price sdo/mdo somewhat lower
price eros two year upon inclus bundl
assum rmti exist relationship translat quicker extens
trifer iv adopt segment though think freseniu adopt meaning
well think well-execut iv launch could conserv translat us sale
put total us trifer revenu dialys plu iv
manag estim us market opportun trifer comfort
number
assum success partner gain approv trifer iv ex-u geographi
includ eu japan china model mileston payment compani
outsid mileston upon china approv assum occur model
assum royalti mid-teen mid-twenti percent rang yield revenu
us estim think conserv size given
manag estim intern end-us revenu opportun rang
china latam canada europ japan
page
busi
big part thesi
rockwel actual second largest supplier hemodialysi concentr us behind
freseniu suppli market bring annual revenu howev
gross margin busi gener quit low single-digit rang manag
initi grow revenu improv profit model assum
page
statesdialysi in-cent hemodialysi elig popul treat sdos/independ treat treat treat trifericaddress popul dialys trifer market trifer net revenu per per net revenu per dialys trifer revenu dialys trifer revenu y/i chang trifericaddress popul iv trifer market trifer patients- net revenu per per net revenu per iv trifer revenu popul iv trifer market trifer patients- net revenu per per net revenu per iv trifer revenu popul iv trifer market trifer patients- net revenu per per net revenu per iv trifer revenu iv trifer revenu y/i chang trifer end-us trifer end-us trifer royalti product royalti model
much contribut busi assum segment grow
show cog separ trifer cog line clariti
go incom statement assum trifer realiz pharmaceutical-lik gross
margin though note includ royalti net sale iv dialys
certain circumst royalti declin conservat
assum royalti durat model assum rel littl way
 spend model relat nda file pediatr trial may
chang depend potenti collabor agreement eu partner
compani choos fund eu trial sg spend assumpt reflect rel
small special sale forc believ requir effect market trifer
assum cash runway recent follow-on assum full exercis
overallot assum net incorpor
mileston payment model upon trifer approv china model
potenti up-front payment collabor geographi could extend
rmti cash runway assum larger equiti rais around carri upon
trifer iv fda approv equiti rais
rockwel hold trifer formul patent cover iv trifer dialys us eu
japan geographi expir see orang book list exhibit
note drug composition-of-matt patent expir inde rockwel first
licens trifer time ago back assum ex-u partner
retain exclus time point
trifer orang book-list patent expiri
page
believ appropri valuat approach commercial-stag entiti
appli discount p/ multipl primari valuat methodolog justif one-
year price target share appli multipl revenu estim
discount back per year assum share note
discount commerci mid-cap biotech compani make rmti peer group
current trade consensu revenu estim see howev think
discount appropri given trifer histori execut challeng new manag
team face valuat trend among renal peer design orang exhibit
sensit analysi valuat revenu
note renal compani highlight orang
page
describ primari valuat methodolog share multipl
appli revenu estim also find valuabl exercis evalu potenti cash
flow gener per-product basi sum-of-part sop analysi see view
approach supplement primari p/ method show sop analysi
includ contribut trifer dialys iv us well royalti revenu eu
japan china latam sale analysi suggest fair valu per share line
primari p/ deriv target
page
discountdrugsum pvsvalu per share equiti dialys iv concentr valu net
stuart paul presid chief execut offic
mr paul year experi dilig execut commerci strategi
healthcar industri prior rockwel mr paul serv corpor offic vice presid
abbott lab role oversaw integr aler also lead largest
global busi unit vice presid gener manag quest
diagnost east region guid revamp lab patient servic
commerci busi mr paul privat equiti gambro ab
time led profit expans asia-pacif america renal therapeut
busi integr combin baxter-gambro renal busi latin america
mr smith current overse financi oper investor relat rockwel prior
role varieti posit includ senior vice presid
chief busi offic princip offic earlier serv vice presid
busi develop strateg plan vice presid corpor
financ pernix mr smith work healthcar invest bank cantor
fitzgerald gleacher compani provid strateg financi advisori servic
dr pratt join chief medic offic april prior rockwel work shire
varieti role across clinic develop time dr pratt oversaw fda
approv fosrenol esrd indic ckd non-dialysi indic shire
senior director clinic research develop eisai medic research
earlier career serv assist professor john hopkin univers cornel
medic colleg depart medicin nephrolog also assist chief
nephrolog director dialysi servic walter reed armi medic center
dr gupta join chief scientif offic sab board member prior rockwel
associ professor medicin ucla charl drew univers school
medicin also held activ nephrolog practic dr gupta also serv faculti
washington univers st loui state univers new york syracus univers
alabama birmingham henri ford hospit also current maintain nephrolog
practic volunt faculti univers california irvin dr gupta invent
process deliv solubl ferric pyrophosph parenter via dialys hemodialysi
periton dialysi patient hold number patent diagnost test medic
devic drug
jim mccarthi svp busi corpor develop
mr mccarthi hold year experi across variou busi develop role
life scienc bristol-my squibb year focus heavili
grow busi oper improv financi posit small emerg
compani across rang therapeut area mr mccarthi also experi licens
deal strateg allianc acquisit domest intern also
recipi licens execut societi presid award
michael deyoung vice-president oper
mr deyoung overse rockwel oper team includ manufactur logist
company-wid strategi deploy prior rockwel chief offic zdgf
hold group director moog medic devic group respons financ hr
page
oper earlier career mr deyoung gambro ab lead oper initi
success sale compani baxter also guid integr baxter
gambro renal oper latin america
ann boardman vice-president sale strateg account
ms boardman year experi across medic biotech renal sale
larg corpor account manag offer deep knowledg renal provid
reimburs dynam rockwel ms boardman serv director integr health
system baxter vice presid strateg account gambro ab also previous
work genzym therapeut orthobiotech watson nephrolog
charli shiner vice-president market
mr shiner success track record grow brand across number pharmaceut
healthcar compani rockwel serv market franchis leader
otsuka renal portfolio play key role launch jynarqu mr shiner
also held role director senior project manag digit market otsuka work
cardio-ren product profession consum channel earlier career
decad manag hospit account across unit state
page
risk associ common biotech compani describ
detail
regulatori risk rockwel success depend larg part regulatori approv trifer iv
rockwel believ suffici data fda approv possibl fda may
request addit data base novemb guidanc rockwel believ
trifer iv elig add-on reimburs tdapa program approv
howev doesnt consid trifer iv new drug dialys
approv may deem inelig tdapa reimburs bundl howev
issu separ code powder ampul form trifer dialys serv
preced consid iv dialys form separ drug
commerci risk us dialysi market highli concentr freseniu
account almost three-quart total hd market success commerci
trifer depend adopt trifer organ rockwel exist
relationship concentr busi like gain initi traction
market segment whether freseniu market adopt less certain
rockwel need establish collabor effect market drug outsid unit
competit risk describ previous trifer enter market long-domin
esa iv iron chang renal anemia market take place concurr
trifer iv launch hif compound come market start directli
compet trifer rockwel need differenti trifer quickli gain share voic
nephrolog commun success launch
clinic risk part trifer valu proposit cost save creat decreas esa/iv iron
use howev rockwel gener rel littl data support conclus though
process gener real-world data may support gain approv eu
rockwel futur eu partner need conduct trial evalu esa spare endpoint
may eventu submit fda includ label
ip risk rockwel issu formul patent cover iv trifer dialys us
eu japan geographi expir howev composition-of-matt patent
expir risk competitor could tri manufactur gener trifer without
violat formul patent
page
statement oper
dollar except per share data
royalti collabor revenu
good sold
product sale
total revenu
sell gener administr
total revenu
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
